Figure 2
From: A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis
Validation of the VEGF-dependent gene signature.
(A) Downregulation of the VDGs following anti-VEGF treatment in the ApcMin genetic tumor model. (B) Downregulation of the VDGs following anti-VEGF treatment in an orthotopic 66c14 mouse breast cancer model. (C) Downregulation of the VDGs following anti-VEGF treatment in a subcutaneous human breast carcinoma MDA-MB-231 model. (D) Changes of the VDGs scores in serial clinical specimens collected from breast cancer patients treated with neoadjuvant bevacizumab.
